ThioTEPA
From Wikipedia, the free encyclopedia
ThioTEPA
|
|
Systematic (IUPAC) name | |
N,N ' N '-triethylenethiophosphoramide | |
Identifiers | |
CAS number | 52-24-4 |
ATC code | L01AC01 |
PubChem | 5453 |
Chemical data | |
Formula | C6H12N3PS |
Mol. weight | 189.219 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic (CYP2B6, CYP2C11) |
Half life | 2.4 hours 15-18 hours (metabolites) |
Excretion | Renal |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status | |
Routes | IV, intracavitary, intravesical |
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N' '-triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It's main toxicity is myelosuppression.
[edit] References
- Sykes M et al. (1953). "Clinical Studies of triethylenephosphoramide compounds with nitrogen mustard-like activity". Cancer 6: 142-48.
- Maanen MJ, Smeets CJ, Beijnen JH (2000). "Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA)". Cancer Treat Rev 26 (4): 257-68. PMID 10913381.